Laddar populära aktier...
Redeye endorses that CLS’ partner, ClearPoint Neuro, has received FDA (510k) clearance for its Prism...
Sales -10% vs. ABGSCe, but EBIT in line at SEK 0m New customer signings in NW&FT and GC&MP to grow s...
Loihde’s Q1 was a pleasant surprise, as we had expected a softer start to the year.
Redeye update on Embracer ahead of Q4-results (due 23 May) where we also adjust our estimates follow...
Solteq’s Q1 results were slightly weaker than expected and revenue declined slightly y/y in comparab...
Aktieanalytiker Mathias Carlson intervjuar VD Torbjörn Saxmo efter publicerad Q1-rapport.
- More positive news for Scandpower - Profitability has always been volatile - Minor revisions with ...
- Slowdown in Q2 before acceleration occurs in H2'24 - 23% adj.
- Quarterly miss brings down CEPS 2024e by -4% - Awaiting news on Polish acquisition agenda - Share ...
Beijer Alma överträffade Analysguidens förväntningar med en tillväxt som både var organisk och förvä...
Softer Q1 than expected, but with solid progress for Private We cut '24e-'26e EBIT by 22-6% on lower...
Förvaltningsresultat sjönk med drygt 6% på årsbasis drivet av en högre genomsnittlig räntenivå.
Snow removal supports strong Q1 (7% EBITA growth) '24e-'26e adj.
Q-linea has secured a US FDA approval, which is positive.
Redeye has updated its estimates for Carasent following the Q1 2024 report, which was more or less i...